Genetic Signatures (ASX:GSS) Dividends Paid: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures Dividends Paid?

Genetic Signatures ASX:GSS Dividends Paid is A$0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Genetic Signatures's Dividends Paid for the six months ended in Dec. 2025 was A$0.00 Mil.

Genetic Signatures's Dividends Paid for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Genetic Signatures Dividends Paid Related Terms

Genetic Signatures Dividends Paid Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's Dividends Paid can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures Dividends Paid Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Dividends Paid
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends Paid Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Signatures Dividends Paid Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Dividends Paid represents dividend paid to the investors in the direct cash flow method.

Dividends Paid for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividends Paid →
What does a Dividends Paid of A$0.00 Mil mean?
Genetic Signatures (ASX:GSS) has a Dividends Paid of A$0.00 Mil as of Dec. 2025. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Genetic Signatures and its competitors.
Is Genetic Signatures' Dividends Paid too high?
Genetic Signatures' current Dividends Paid is A$0.00 Mil.
How does Genetic Signatures' Dividends Paid compare to TMO and DHR?
Genetic Signatures' Dividends Paid of A$0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends Paid for a Medical Diagnostics & Research company?
A good Dividends Paid depends on the Medical Diagnostics & Research industry context. However, Dividends Paid should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends Paid mean?
A high Dividends Paid can signal that a stock is expensive relative to its fundamentals. Dividends Paid represents dividend paid to the investors in direct cash flow method. View historical data for Genetic Signatures and its competitors. Genetic Signatures's current Dividends Paid is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.06 — trading 84.7% below its estimated fair value. The current Dividends Paid is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends Paid calculated?
Dividends Paid is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Dividends Paid is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.